Pharmaphorum, one of the pharmaceutical industry’s most widely read analysis platforms, published a feature by Ali Pashazadeh, Founder and CEO of Treehill Partners, in March 2026 reviewing the key themes and findings from the J.P. Morgan Healthcare Conference. The article draws on Treehill’s programme of structured roundtable discussions at JPM 2026, which convened biotech CEOs, large pharma BD heads, and investors to assess where the industry stands.
A Recovery Built on Substance, Not Spectacle
The piece describes a conference atmosphere defined by purposeful activity rather than performative confidence. There were no headline mega-deals. Instead, participants reported something more substantive: real engagement. Investor conversations that had been absent for years were returning, and transactions stalled for six months or longer were showing signs of movement. The traditional venture model — a portfolio approach premised on a small number of outsized wins compensating for many failures — is increasingly misaligned with current capital allocation priorities. Ali characterises this not as a temporary dislocation but as a structural shift demanding new approaches to how biotech companies are built, funded, and valued.
The Development Gap and the Eastern Challenge
A consistent finding across Treehill’s roundtables was that drug development strategy remains the area most in need of improvement. Analysis continues to suggest that approximately 85 percent of clinical studies could be designed more efficiently. Contract research organisations have strong operational capability but have not consistently filled the strategic gap.
Meanwhile, the maturation of Asian biotechnology — particularly from China and Korea — represents the most significant structural development visible at JPM 2026. Leading Chinese companies now compete directly with large pharmaceutical organisations on scientific merit, often achieving early clinical signal at a fraction of comparable Western expenditure. China accounts for approximately 20 percent of all drugs in global development, nearly double the combined share of the five largest European markets.
The Agility Imperative
The article concludes that the industry’s tolerance for deviation from fundamentals has evaporated. Sound science, rigorous development, realistic positioning, and effective execution remain the prerequisites for success. What has changed is that companies can no longer compensate for weakness in one area with strength in another. For the companies and organisations that adapt to this reality, the current environment represents genuine opportunity — but only for those prepared to meet it on its own terms.
Read the full article on: https://pharmaphorum.com/market-access/jpm-2026-what-it-revealed-about-biotechs-new-reality
📌 Treehill Partners – helping biopharma companies optimize development strategies for both regulatory approval and commercial success, unlocking transaction optionality with strategic and financial players.